Aranda-Flores CE

Language: Spanish
References: 21
Page: 697-706
PDF size: 461.36 Kb.

ABSTRACT

Objective: Review updated (HPV) HPV in Man virus information, the role as a sexually transmitted infection (STI) that negatively impacts your partner (s) sexual (s) and represents a public health problem globally. In the case of men they have been identified specific risk factors that place it as the main factor in the transmission of the disease (infection, cancer and cancer precursor lesions in the genital tract), both heterosexual and homosexual practice as the subjects infected with HIV (HIV) in whom HPV prevalence rises to 95%.
Search methodology: A systematic review of the literature of the past six years to date (2015) was made. Human papilloma virus vaccine, warts and sexually transmitted: In the database PubMed , LILACS and EMBASE were searched keywords . Only items that directly related to studies in men and that referred to the vaccine were analyzed.
Results: The mean time of disappearance of persistent injuries HPV-6, 11, 16, and 18 (defined as two consecutive negative results) was 6.7; 3.2; 9.2; and 4.7 months respectively. In conclusion, this study showed that the acquisition of HPV-6, 11, 16, or 18 is common among men. Differences in detection rates of HPV DNA in anogenital different anatomical sites were found. It has been found that the average time of disappearance of lesions is ≥6 months. In another study conducted on a sample that included Mexican population, the median duration of HPV infection was 7.52 months (6.80-8.61) for any type of HPV and 12-19 months (7.16-18.17) for HPV -16.
Conclusion: The prevention of this disease has had a significant change with the introduction of the HPV vaccine, which has led organizations like the World Health Organization (WHO) to take a position in favor of including these biological in national immunization programs, to thereby contribute to the eradication of not only genital cancer in women, also in man, which is being reflected gradually in such programs

REFERENCES

1. Hull S, Caplan A. The case for vaccinating boys against Human Papillomavirus. Public Health Genomics 2009;12:362- 367.

2. Goldstone S, Jessen H, Palefsky J, Giuliano A, Moreira E, et al. Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. Vaccine 2013;31:3849-3855.

3. Crosignani P, De Stefani A, Fara GM, Isidori AM, et al. Towards the eradication of HPV infection through universal specific vaccination. BMC Public Health 2013;13:642-652.

4. Giuliano AR, Anic G, Nytray AG. Epidemiology and pathology of HPV disease in males. Gynecologic Oncology 2010;117:2 Supplement, S15-S19.

5. Newman PA, Logie CH, Doukas N, Asakura K. HPV vaccine acceptability among men: a systematic review and metaanalysis. Sex Transm Infect 2013;89:568-574.

6. Programa de acción específico. Respuesta al VIH, SIDA e ITS, 2013-2018. Programa sectorial de salud. Consultado el 28 de febrero de 2015 en: http://www.censida.salud.gob. mx/descargas/acerca/PAE_2013_2018_AUTORIZADA.pdf

7. Gross G. Genitoanal HPV infection and associated neoplasias in the male. G. Gross and S.K. Tyring (eds), Sexually Transmitted Infections and Sexually Transmitted Diseases, DOI: 10.1007/978-3-642-14663-3_37, Springer-Verlag Berlin Heidelberg 2011.

8. Rosenblatt A, de Campos-Guidi G. Human papillomavirus history and epidemiology. A. Rosenblatt, H. G. de Campos Guidi, Human Papillomavirus, DOI:10.1007/978-3-540- 70974-9-1, Springer-Verlag Berlin Heidelberg 2009.

9. Duarte Moreira E, Giuliano AR, Palefsky J, Aranda Flores C, Goldstone S, et al. Incidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual men. J Infect Dis. 2014 Jul 15;210(2):192-9.

10. Giuliano A, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011 March 12;377(9769):932-940.

11. Encuesta Nacional de Salud y Nutrición 2012. Resultados nacionales. INSP, México, consultada el 5 de marzo en: http://ensanut.insp.mx/informes/ENSANUT2012ResultadosNacionales. pdf

12. Weekly epidemiological record: World Health Organization. 2014; 43:43-492

13. Anic G, Giuliano A. Genital HPV infection and related lesions in men. Preventive Medicine 2011;53:S36-S41.

14. Lazcano-Ponce E, Salmeron-Castro, García Carrancá A, Aranda-Flores C, et al. Recomendaciones para la definición contra el virus del papiloma en México. Salud Pública de México 2009; 51(4):336-341.

15. Carvalho N, Teixeira J, Roteli-Martins CM, Naud P, De Borba P, et al. Sustained efficacy and immunogenicity of the HPV- 16/18 AS04-ajunvanted vaccine up to 7.3 years in young adult women. Vaccine 2010;28:6247-6255.

16. Moreira E, Palefsky J, Giuliano A, et al. Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults. Human vaccines 2011;7(7):1-8.

17. Levin M, Moscicki AB, Song LY, Fenton T, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine in HIV- infected children 7 to 12 years old. J Acquir Immune Defic Syndr. 2010;55(2):197-204.

18. Swedish K, factor S, Goldstone S. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a no concurrent cohort study. Clinical Infectious Diseases 2012;54(7):891-8

19. Giuliano A, Palefsky J, Goldstone S, Moreira E, Penny M, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011; 364(5):401-11

20. Palefsky J, Giuliano A, Goldstone S, Moreira E, Aranda C, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365:1576-1585.

21. HPV vaccine? Only in females? Think again! British Columbia Drug and Poison Information Centre (BC DPIC). Consultado el 15 de abril de 2015 en: http:// www.dpic.org